Arab Press

بالشعب و للشعب
Friday, Jun 20, 2025

Efficacy of Pfizer’s Covid-19 pill questioned

Efficacy of Pfizer’s Covid-19 pill questioned

An Israeli study has indicated the medication is of little measurable benefit to patients in the 40-65 age bracket
A Covid-19 pill lauded by the World Health Organization (WHO) may be of little or no benefit to patients aged between 40 and 65, a new study by Israeli researchers has suggested. The medication, made by Pfizer and sold under the trade name Paxlovid, has proven effective in those aged over 65, however.

Published in the New England Journal of Medicine on Wednesday, the study involved 109,000 patients who had received Paxlovid. After analyzing different age brackets, the scientists concluded that the treatment did little to improve the conditions of patients aged 40 to 65. At the same time, the medication reduced the number of hospitalizations among seniors by approximately 75%, if given shortly after contracting Covid-19.

The analysis, however, is based on data obtained from the Israeli health system as opposed to observing patients in a randomized study with a control group – something which represents a departure from practices held as the standard for such research, AP pointed out.

No official comment from Pfizer has been forthcoming as of yet.

The US Food and Drug Administration authorized Paxlovid late last year for adults and children over 12 who suffer from chronic conditions like obesity, diabetes and heart disease. According to federal records cited by AP, over 3.9 million prescriptions for the medication have been issued since the drug was given the green light.

The Biden administration has been placing particular emphasis on Paxlovid in the hope of reducing the number of hospitalizations. US authorities are said to have shelled out some $10 billion to procure the drug, which is being made available to the public at thousands of pharmacies through the government’s test-and-treat initiative.

In an emailed statement on Wednesday, White House spokesperson Kevin Munoz cited several other studies which indicate that Paxlovid helps reduce hospitalizations among people 50 and older. That research, however, has yet to be published in peer-reviewed journals, AP noted.

The official was quoted as saying that the “growing body of evidence is showing that individuals between the ages of 50 and 64 can also benefit from Paxlovid.”
Comments

Oh ya 3 year ago
I think I read somewhere it was the liver and kidneys that it also is harmful to. But of you have taken the shot and especially the boosters then this pill is the least of your problems

Newsletter

Related Articles

Arab Press
0:00
0:00
Close
16 Billion Login Credentials Leaked in Unprecedented Cybersecurity Breach
Senate hearing on who was 'really running' Biden White House kicks off
G7 Leaders Fail to Reach Consensus on Key Global Issues
Mass exodus in Tehran as millions try to flee following Trump’s evacuation order
Iranian Military Officers Reportedly Seek Contact with Reza Pahlavi, Signal Intent to Defect
China's Iranian Oil Imports Face Disruption Amid Escalating Middle East Tensions
Trump Demands Iran's Unconditional Surrender Amid Escalating Conflict
Israeli Airstrike Targets Iranian State TV in Central Tehran
President Trump is leaving the G7 summit early and has ordered the National Security Council to the Situation Room
Netanyahu Signals Potential Regime Change in Iran
Analysts Warn Iran May Resort to Unconventional Warfare
Iranian Regime Faces Existential Threat Amid Conflict
Energy Infrastructure Becomes War Zone in Middle East
Iran Conducts Ballistic Missile Launches Amid Heightened Tensions with Israel
Iran Signals Openness to Nuclear Negotiations Amid Ongoing Regional Tensions
Shock Within Iran’s Leadership: Khamenei’s Failed Plan to Launch 1,000 Missiles Against Israel
UK Deploys Jets to Middle East Amid Rising Tensions
Exiled Iranian Prince Reza Pahlavi Urges Overthrow of Khamenei Regime
Wreck of $17 Billion San José Galleon Identified Off Colombia After 300 Years
Iran Launches Extensive Missile Attack on Israel Following Israeli Strikes on Nuclear Sites
Israel Issues Ultimatum to Iran Over Potential Retaliation and Nuclear Facilities
Coinbase CEO Warns Bitcoin Could Supplant US Dollar Amid Mounting National Debt
Trump to Iran: Make a Deal — Sign or Die
Operation "Like a Lion": Israel Strikes Iran in Unprecedented Offensive
Israel Launches 'Operation Rising Lion' Targeting Iranian Nuclear and Military Sites
Israeli Forces Intercept Gaza-Bound Aid Vessel Carrying Greta Thunberg
IMF Warns of Severe Global Trade War Impacts on Emerging Markets
Syria to Reconnect to Global Economy After 14 Years of Isolation
Saudi Arabia Faces Uncertainty Over Succession After Mohammed bin Salman
Israel Confirms Arming Gaza Clan to Counter Hamas Influence
Majority of French Voters View Macron's Presidency as a Failure
U.S. Reduces Military Presence in Syria
Trump Demands Iran End All Uranium Enrichment in Nuclear Talks
Iran Warns Europe Against Politicizing UN Nuclear Report
Businessman Mauled by Lion at Luxury Namibian Lodge
Paris Saint-Germain's Greatest Triumph Is Football’s Lowest Point
OPEC+ Agrees to Increase Oil Output for Third Consecutive Month
Turkey Detains Istanbul Officials Amid Anti-Corruption Crackdown
Meta and Anduril Collaborate on AI-Driven Military Augmented Reality Systems
EU Central Bank Pushes to Replace US Dollar with Euro as World’s Main Currency
European and Arab Ministers Convene in Madrid to Address Gaza Conflict
Head of Gaza Aid Group Resigns Amid Humanitarian Concerns
U.S. Health Secretary Ends Select COVID-19 Vaccine Recommendations
Trump Warns Putin Is 'Playing with Fire' Amid Escalating Ukraine Conflict
India and Pakistan Engage Trump-Linked Lobbyists to Influence U.S. Policy
U.S. Halts New Student Visa Interviews Amid Enhanced Security Measures
Trump Administration Cancels $100 Million in Federal Contracts with Harvard
SpaceX Starship Test Flight Ends in Failure, Mars Mission Timeline Uncertain
King Charles Affirms Canadian Sovereignty Amid U.S. Statehood Pressure
Iranian Revolutionary Guard Founder Warns Against Trusting Regime in Nuclear Talks
×